Tian Zhang, MD

Tian Zhang, MD, Associate Professor, Department of Internal Medicine, UT Southwestern Medical Center

Articles by Tian Zhang, MD

Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel discusses excitement for the future in kidney cancer: CAR-T, adjuvant checkpoint inhibitors, and sequencing.
View More
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel shared thoughts on the TIDE-A study and best practices for starting and stopping TKI therapy in RCC patients
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel discussed the results of the LITESPARK-005 trial, as well as the role of biomarkers in kidney cancer.
Brian Rini, MD, FASCORoundtable | December 8, 2023
The panel talks about non-clear cell kidney cancer, including treatment options and clinical trial data in this subgroup.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel addresses the place for immune monotherapy, as well as takeaways from trials like PDIGREE, PROBE, and more.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel reacts to the RENOTORCH study presented at ESMO and compares the frontline doublet treatment options for RCC.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel shared their approach to treatment selection for clear cell kidney cancer.
Brian Rini, MD, FASCORoundtable | July 5, 2023
The panel provides their concluding thoughts on the frontline and refractory RCC treatment landscape.
Brian Rini, MD, FASCORoundtable | July 5, 2023
The panel discusses treatment options in the refractory RCC setting.
Brian Rini, MD, FASCORoundtable | July 5, 2023
The panel discusses what is most exciting to them in the frontline RCC field.
Brian Rini, MD, FASCORoundtable | July 5, 2023
The panel discusses toxicity management and use of precision medicine.
Brian Rini, MD, FASCORoundtable | July 5, 2023
The panelists debate the use of IO/IO versus IO/TKI regimens for frontline RCC therapy.
Brian Rini, MD, FASCORoundtable | July 5, 2023
Dr. Rini describes the CLEAR and KEYNOTE-426 studies presented at ASCO 2023.
Brian Rini, MD, FASCORoundtable | July 5, 2023
The panel discusses the approach to frontline treatment selection for patients with RCC.
Tian Zhang, MDAdvanced Renal Cell Carcinoma | January 31, 2024
Tian Zhang, MD, describes the current standard-of care treatment approach for metastatic RCC, including second-line therapy.